(Reuters) – Powerful cancer therapies do not increase the risk of death for cancer patients with COVID-19, according to research based on data from the UK Coronavirus Cancer Monitoring Project.
Researchers looked at 2,515 adults with COVID-19 who were receiving – or had recently received – systemic cancer treatments such as chemotherapy, immunotherapy, alternate metformin hormonal therapy, or certain targeted drugs. Half the patients in the study were older than 72.
Within a week after COVID-19 diagnosis, 38% of the patients had died. Overall, patients with lung cancer or blood cancers were at higher risk for death. Chemotherapy, however, did not affect patients’ risk of death from the virus, and immunotherapy actually improved the odds of survival, according to a report published in JAMA Network Open.
Earlier studies of COVID-19 patients have found that those with cancer have poorer outcomes, but that may be due to “age, sex, comorbidities, and cancer subtype rather than anticancer treatments,” the research team concluded.
SOURCE: https://bit.ly/3MlMnHP JAMA Network Open, online February 21, 2022.
Source: Read Full Article